

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2017/087594 A1

(43) International Publication Date

26 May 2017 (26.05.2017)

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(51) International Patent Classification:

A61K 47/48 (2006.01) A61P 25/16 (2006.01)  
A61K 9/14 (2006.01)

(21) International Application Number:

PCT/US2016/062400

(22) International Filing Date:

17 November 2016 (17.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/257,533 19 November 2015 (19.11.2015) US

(71) Applicant: BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. [US/US]; 234 Church Street, Suite 301, New Haven, CT 06520 (US).

(72) Inventor: MARFAT, Anthony; 333 Lantern Hill Road, Mystic, CT 06355 (US).

(74) Agents: VOLLES, Warren K. et al.; IPraXus Legal, LLC, P.O. Box 689, Old Lyme, CT 06371 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))



WO 2017/087594 A1

(54) Title: AMINE PRODRUGS OF PHARMACEUTICAL COMPOUNDS

(57) Abstract: Disclose are amine prodrugs and methods of synthesis thereof. In particular, the amine prodrug comprises a drug molecule and at least one or more prodrug appendage moieties and the method for synthesis the amine prodmg comprises a step of coupling the drag molecule and at least one or more prodrug appendage moieties. Also disclosed are exemplary riluzole prodrugs and methods of synthesis thereof.

## AMINE PRODRUGS OF PHARMACEUTICAL COMPOUNDS

### CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of and priority to U.S. Provisional Application Ser. No. 62/257,533 filed November 19, 2015, the disclosure of which is herein incorporated by reference in its entirety.

### TECHNICAL FIELD

[0002] The present invention relates to amine prodrugs and methods of synthesis thereof. The amine prodrug comprises a drug molecule and at least one or more prodrug appendage moieties. The method of synthesis thereof comprises a step of coupling the drug molecule and at least one or more prodrug appendage moieties.

### BACKGROUND

[0003] Discovery of novel prodrugs has been an integral part in current pharmaceutical industry. A prodrug is an alternative form of a drug and is used instead to improve absorbed, distributed, metabolized and excreted (ADME) properties of the drug. The prodrug is administered in an inactive or less active form, and is subsequently converted to its active drug through a normal metabolic process, such as hydrolysis or other chemical reactions, in a subject.


[0004] Among commercially available prodrug products, amine prodrugs such as Capecitabine (Xeloda), Docarpamine, Prulifloxacin, Gabapentin enacabril, and Altrofloxacin have been successfully introduced into market. The primary or secondary amine prodrugs have been made substantially and further prodrugs of tertiary amine or quaternary amine have been also made and are being advanced into clinical development as well. (Prodrugs of Amines, Ana L. Simplicio et al, Molecules, 2008,13 519-547; Prodrugs of Amines, Jeffrey Krise et al, Prodrugs, Challenges and Rewards Part 1 and Part 2, Springer new York, 2007; Drug Synthesis II, presentation by Tapio Nevalainen, University of Eastern Finland, 2012.)

[0005] As such, other amine prodrugs are potential candidates for drug development.

**SUMMARY OF THE INVENTION**


[0006] The present invention provides amine prodrug and methods of synthesis thereof.


[0007] In one aspect, the present invention provides a prodrug which comprises a drug molecule and at least one or more prodrug appendage moieties. The prodrug may be formed as:



[0008] In particular, the prodrug appendage moiety may be coupled to amine of the drug molecule. In this prodrug of the present invention,  $i$  may be 1 or 2 and  $j$  may be 0 or 1. For example,  $i$  is 1 and  $j$  is 1; or  $i$  is 2 and  $j$  is 0.

[0009] The prodrug appendage moiety may be independently selected from the group of consisting of:





where  $R^1$  may be H, alkyl or particularly  $C_1$ - $C_8$  alkyl;

$R^2$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted,

$R^3$  may be H, metal,  $R^2$  or a substituted or unsubstituted primary, secondary or tertiary amine;

$R^4$  may be H, metal, ammonium salt, or alkyl;

$R^5$  may be a substituted or unsubstituted natural amino acid;

$R^a$  or  $R^b$  may be H, alkyl or aryl; or  $NR^a$  or  $NR^b$  may be an amino acid;

X may be C or O;

k may be 1 or 2, m may be 2-22, or  $(CH_k)_m$  may be saturated, unsaturated or conjugated hydrocarbon;


n may be 0 – 2; and

the metal may be Na, K, Li, Ca, Mg, Ag or Zn.

In an exemplary embodiment, and the drug molecule may be riluzole.


[0010] In another aspect, the present invention provides a method of preparing a prodrug.

[0011] In one embodiment, a method of preparing a riluzole prodrug is provided. The method comprises a step of coupling one or more prodrug appendage moieties to a riluzole molecule as described below.



[0012] In particular, the prodrug appendage moiety may be coupled to amine of the riluzole molecule where i may be 1 or 2 and j may be 0 or 1. For example, i is 1 and j is 1; or i is 2 and j is 0.

[0013] The prodrug appendage moiety may be independently selected from the group of consisting of:



where  $R^1$  may be H, alkyl or particularly  $C_1-C_8$  alkyl;

$R^2$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted,

$R^3$  may be H, metal,  $R^2$  or a substituted or unsubstituted primary, secondary or tertiary amine;

$R^4$  may be H, metal, ammonium salt, or alkyl;

$R^5$  may be a substituted or unsubstituted natural amino acid:

$R^a$  or  $R^b$  may be H, alkyl or aryl; or  $NR^a$  or  $NR^b$  may be an amino acid;


X may be C or O;

k may be 1 or 2, m may be 2-22, or  $(CH_k)_m$  may be saturated, unsaturated or conjugated hydrocarbon;

n may be 0 – 2; and

the metal may be Na, K, Li, Ca, Mg, Ag or Zn.

[0014] Exemplary riluzole prodrug may be:





where  $R^1$  may be H, alkyl or particularly  $C_1-C_8$  alkyl;  $R^2$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted;  $R^3$  may be H, metal,  $R^2$  or a substituted or unsubstituted primary, secondary or tertiary amine;  $R^4$  may be H, metal, ammonium salt, or alkyl;  $R^6$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl;  $N'$  may be a primary,


secondary and tertiary amine which may be substituted or unsubstituted, or metal salts; and Y may be  $\text{PO}_3\text{H}$ ,  $\text{CH}_2\text{PO}_2\text{H}$  or salt thereof. In particular, the metal may be Na, K, Li, Ca, Mg, Ag or Zn.

[0015] The present invention also provides a method of synthesizing a riluzole prodrug.








[0016] In one embodiment, the method comprises a step of reacting riluzole with



to produce



[0017] The method further comprises a step of reacting with a compound selected from the group consisting of:



and

where  $\text{R}^1$  may be H, alkyl or particularly  $\text{C}_1\text{-C}_8$  alkyl;

$\text{R}^2$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted;

$\text{R}^4$  may be H, metal, ammonium salt, or alkyl;

$\text{k}$  may be 1 or 2,  $\text{m}$  may be 2-22, or  $(\text{CH}_k)_m$  may be saturated, unsaturated or conjugated hydrocarbon;

Bc may be a protecting group;

Y' may be H,  $\text{PO}_3\text{Bc}_2$ ,  $\text{CH}_2\text{PO}_2\text{Bc}$ ,  $\text{MPO}_3\text{Bc}$  or salt thereof, or  $\text{N}(\text{R}_a)_4^+$ , where  $\text{R}_a$  is H or alkyl;


M may be a metal such as Na, K, Li, Ca, Mg, Ag or Zn; and

R' or R" may be cyclic or acyclic alkyl.


**[0018]** In one embodiment, the method of synthesizing a riluzole prodrug comprises a step of reacting a riluzole, with  $\text{CO}_2$ ,  $\text{Cs}_2\text{CO}_3$  and reacting the resulting compound with




**[0019]** In one embodiment, the method of synthesizing a riluzole prodrug comprises a step of



**[0020]** In one embodiment, the method of synthesizing a riluzole prodrug comprises a step of



**[0021]** In one embodiment, the method of synthesizing a riluzole prodrug comprises a step of




wherein  $\text{R}^1$  may be H, alkyl or particularly  $\text{C}_1\text{-C}_8$  alkyl;

$\text{R}^2$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and

$\text{R}^3$  may be H, metal,  $\text{R}^2$  or a substituted or unsubstituted primary, secondary or tertiary amine.

[0022] In one embodiment, the method of synthesizing a riluzole prodrug comprises a step of reacting riluzole with  $((\text{PhCH}_2\text{O})_2\text{PO})_2\text{O}$  and sodium bis(trimethylsilyl)amide (NaHMDS) and subsequently reacting the resulting compound with hydrogen:



where  $\text{R}^6$  may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl; and  $\text{N}'$  may be a primary, secondary and tertiary amine which may be substituted or unsubstituted, or metal salts.

[0023] Other aspects of the invention are disclosed infra.

### **DETAILED DESCRIPTION OF THE INVENTION**

[0024] The following is a detailed description provided to aid those skilled in the art in practicing the present invention. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present disclosure. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting. All publications, patent applications, patents, figures and other references mentioned herein are expressly incorporated by reference in their entirety.


[0025] The following terms are used to describe the present invention. In instances where a term is not specifically defined herein, that term is given an art-recognized meaning by those of ordinary skill applying that term in context to its use in describing the present invention.

[0026] As used in the description of the invention and the appended claims, the singular forms "a", "an" and "the" are used interchangeably and intended to include the plural forms as well and fall within each meaning, unless the context clearly indicates otherwise. Also, as used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the listed items, as well as the lack of combinations when interpreted in the alternative ("or"). Singular word forms are intended to include plural word forms and are likewise used herein interchangeably where appropriate and fall within each meaning, unless expressly stated otherwise.

[0027] The term “prodrug” as used herein, is a precursor of a drug which may be administered in an altered or less active form. The prodrug may be converted into the active drug form in physiological environments by hydrolysis or other metabolic pathways. The prodrug may provide improved physiochemical or physiological characteristics to enhance therapeutic effects of the drug.

[0028] The term “prodrug appendage moiety” as used herein, refers to a chemical group or moiety covalently or non-covalently attached to a drug molecule, thereby produce a prodrug form of the drug. The prodrug appendage moiety may not alter pharmacokinetic core or properties of the drug molecules by intramolecular rearrangement or cleavage. In certain embodiments, multiple prodrug appendage moieties may be attached to the drug molecule, without limitation. In addition, the prodrug appendage moiety may couple one or more of the drug molecules, without limitation.

[0029] The term “riluzole”, as used herein, refers to a drug, 6-(trifluoromethoxy)benzothiazol-2-amine, which is generally used to treat amyotrophic lateral sclerosis (ALS). It is also available in the market as RILUTEK®.



6-(trifluoromethoxy)benzothiazol-2-amine

[0030] As used herein, the term “leaving group,” or “LG”, as used herein, refers to any group that leaves in the course of a chemical reaction involving the group and includes but is not limited to halogen, brosylate, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups, for example.

[0031] As used herein, the term “alkyl” refers to a straight-chained or branched hydrocarbon group containing 1 to 18 (e.g., C<sub>1</sub>-C<sub>18</sub>, inclusive; and any sub-range thereof) carbon atoms. The term “lower alkyl” refers to a C<sub>1</sub>-C<sub>6</sub> alkyl chain. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl (n-, sec-, tert-), and pivaloyl. Alkyl groups may be optionally substituted with one or more substituents.

[0032] The term “cycloalkyl” denotes a non-aromatic mono or multicyclic ring system of 3 to 12 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and examples of

multicyclic cycloalkyl groups include perhydronaphthyl, adamantyl and norbornyl groups bridged cyclic group or spirobicyclic groups e.g spiro(4,4)non-2-yl.

[0033] As used herein, the term "halogen" or "halide" means -F, -Cl, -Br or -I.

[0034] As used herein, the term "haloalkyl" means and alkyl group in which one or more (including all) the hydrogen radicals are replaced by a halo group, wherein each halo group is independently selected from -F, -Cl, -Br, and -I. The term "halomethyl" means a methyl in which one to three hydrogen radical(s) have been replaced by a halo group. Representative haloalkyl groups include trifluoromethyl, difluoromethyl, bromomethyl, 1,2-dichloroethyl, 4-iodobutyl, 2-fluoropentyl, and the like. The term "perhaloalkyl" refers to a alkyl group in which all hydrogen atoms are replaced by a halo group (e.g., trifluoromethyl, pentafluoroethyl). In certain embodiments, the haloalkyl may be an activated alkyl.

[0035] The term "cycloalkyl" refers to a hydrocarbon 3-8 membered monocyclic or 7-14 membered bicyclic ring system having at least one non-aromatic ring. Cycloalkyl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a cycloalkyl group may be substituted by a substituent. Representative examples of cycloalkyl group include cyclopropyl, cyclopentyl, cyclohexyl, cyclobutyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.

[0036] The term "aryl" refers to a hydrocarbon monocyclic, bicyclic or tricyclic aromatic ring system. Aryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, 4, 5 or 6 atoms of each ring of an aryl group may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, anthracenyl, fluorenyl, indenyl, azulenyl, and the like.

[0037] The term "heteroaryl" refers to an aromatic monocyclic, bicyclic, or tricyclic ring system having 1-4 ring heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, and the remainder ring atoms being carbon (with appropriate hydrogen atoms unless otherwise indicated). Heteroaryl groups may be optionally substituted with one or more substituents. In one embodiment, 0, 1, 2, 3, or 4 atoms of each ring of a heteroaryl group may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, 1-oxo-pyridyl, furanyl, benzo[1,3]dioxolyl, benzo[1,4]dioxinyl, thienyl, pyrrolyl, oxazolyl, oxadiazolyl, imidazolyl thiazolyl, isoxazolyl, quinolinyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, triazolyl, thiadiazolyl, isoquinolinyl, indazolyl, benzoxazolyl, benzofuryl, indolizinyl, imidazopyridyl,

tetrazolyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indolyl, tetrahydroindolyl, azaindolyl, imidazopyridyl, quinazolinyl, purinyl, pyrrolo[2,3]pyrimidinyl, pyrazolo[3,4]pyrimidinyl, and benzo(b)thienyl, 3H-thiazolo[2,3-c][1,2,4]thiadiazolyl, imidazo[1,2-d]-1,2,4-thiadiazolyl, imidazo[2,1-b]-1,3,4-thiadiazolyl, 1H,2H-furo[3,4-d]-1,2,3-thiadiazolyl, 1H-pyrazolo[5,1-c]-1,2,4-triazolyl, pyrrolo[3,4-d]-1,2,3-triazolyl, cyclopentatriazolyl, 3H-pyrrolo[3,4-c]isoxazolyl, 1H,3H-pyrrolo[1,2-c]oxazolyl, pyrrolo[2,1b]oxazolyl, and the like.

[0038] As used herein the term “substituent” or “substituted” means that a hydrogen radical on a compound or group (such as, for example, alkyl, alkenyl, alkynyl, alkylene, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cyclyl, heterocycloalkyl, or heterocyclyl group) is replaced with any desired group that does not substantially adversely affect the stability of the compound. In one embodiment, desired substituents are those which do not adversely affect the activity of a compound. The term “substituted” refers to one or more substituents (which may be the same or different), each replacing a hydrogen atom. Examples of substituents include, but are not limited to, halogen (F, Cl, Br, or I), hydroxyl, amino, alkylamino, arylamino, dialkylamino, diarylamino, cyano, nitro, mercapto, oxo (i.e., carbonyl), thio, imino, formyl, carbamido, carbamyl, carboxyl, thioureido, thiocyanato, sulfoamido, sulfonylalkyl, sulfonylaryl, alkyl, alkenyl, alkoxy, mercaptoalkoxy, aryl, heteroaryl, cyclyl, heterocyclyl, wherein alkyl, alkenyl, alkyloxy, aryl, heteroaryl, cyclyl, and heterocyclyl are optionally substituted with alkyl, aryl, heteroaryl, halogen, hydroxyl, amino, mercapto, cyano, nitro, oxo (=O), thioxo (=S), or imino (=NR), wherein R is as defined herein. The substituents on any group (such as, for example, alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroaralkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, and heterocycloalkenyl) can be at any atom of that group, wherein any group that can be substituted (such as, for example, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cyclyl, heterocycloalkyl, and heterocyclyl) can be optionally substituted with one or more substituents (which may be the same or different), each replacing a hydrogen atom. Examples of suitable substituents include, but not limited to alkyl, alkenyl, alkynyl, cyclyl, cycloalkyl, heterocycloalkenyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, aryl, heteroaryl, halogen, haloalkyl, cyano, nitro, alkoxy, aryloxy, hydroxyl, hydroxylalkyl, oxo (i.e., carbonyl), carboxyl, formyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxy carbonyl, alkylcarbonyloxy, aryloxycarbonyl, heteroaryloxy, heteroaryloxycarbonyl, thio, mercapto, mercaptoalkyl, arylsulfonyl, amino, aminoalkyl, dialkylamino, alkylcarbonylamino, alkylaminocarbonyl, or alkoxy carbonylamino; alkylamino,

aryl amino, diaryl amino, alkyl carbonyl, or aryl amino-substituted aryl; arylalkylamino, aralkylaminocarbonyl, amido, alkylaminosulfonyl, arylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, imino, carbamido, carbamyl, thioureido, thiocyanato, sulfoamido, sulfonylalkyl, sulfonylaryl, or mercaptoalkoxy.

[0039] Additional suitable substituents on alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroaralkyl, cycloalkyl, cyclyl, heterocycloalkyl, and heterocyclyl include, without limitation halogen, CN, NO<sub>2</sub>, OR<sup>15</sup>, SR<sup>15</sup>, S(O)<sub>2</sub>OR<sup>15</sup>, NR<sup>15</sup>R<sup>16</sup>, C<sub>1</sub>-C<sub>2</sub> perfluoroalkyl, C<sub>1</sub>-C<sub>2</sub> perfluoroalkoxy, 1,2-methylenedioxy, (=O), (=S), (=NR<sup>15</sup>), C(O)OR<sup>15</sup>, C(O)NR<sup>15</sup>R<sup>16</sup>, OC(O)NR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>C(O)NR<sup>15</sup>R<sup>16</sup>, C(NR<sup>16</sup>)NR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>C(NR<sup>16</sup>)NR<sup>15</sup>R<sup>16</sup>, S(O)<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, R<sup>17</sup>, C(O)H, C(O)R<sup>17</sup>, NR<sup>15</sup>C(O)R<sup>17</sup>, Si(R<sup>15</sup>)<sub>3</sub>, OSi(R<sup>15</sup>)<sub>3</sub>, Si(OH)<sub>2</sub>R<sup>15</sup>, P(O)(OR<sup>15</sup>)<sub>2</sub>, S(O)R<sup>17</sup>, or S(O)<sub>2</sub>R<sup>17</sup>. Each R<sup>15</sup> is independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl optionally substituted with cycloalkyl, aryl, heterocyclyl, aryl, or heteroaryl. Each R<sup>16</sup> is independently hydrogen, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, heterocyclyl, heteroaryl, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> alkyl substituted with C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, heterocyclyl aryl, or heteroaryl. Each R<sup>17</sup> is independently C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, heterocyclyl, heteroaryl, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> alkyl substituted with C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, heterocyclyl or heteroaryl. Each C<sub>3</sub>-C<sub>6</sub> cycloalkyl, aryl, heterocyclyl, heteroaryl and C<sub>1</sub>-C<sub>4</sub> alkyl in each R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> can optionally be substituted with halogen, CN, C<sub>1</sub>-C<sub>4</sub> alkyl, OH, C<sub>1</sub>-C<sub>4</sub> alkoxy, COOH, C(O)OC<sub>1</sub>-C<sub>4</sub> alkyl, NH<sub>2</sub>, C<sub>1</sub>-C<sub>4</sub> alkylamino, or C<sub>1</sub>-C<sub>4</sub> dialkylamino.


[0040] The recitation of a listing of chemical groups in any definition of a variable herein includes definitions of that variable as any single group or combination of listed groups. The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.

[0041] The compounds disclosed in the present invention are available from commercial sources or may be synthesized using reagents and techniques known in the art, including those delineated herein. The chemicals used in the synthetic routes may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents. The methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds herein. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the applicable compounds are known in the art and include, for example, those described in R. Larock, *Comprehensive Organic Transformations*, VCH Publishers


(1989); T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, 3<sup>rd</sup> Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, *Fieser and Fieser's Reagents for Organic Synthesis*, John Wiley and Sons (1994); and L. Paquette, ed., *Encyclopedia of Reagents for Organic Synthesis*, John Wiley and Sons (1995) and subsequent editions thereof.

#### PRODRUG APPENDAGE MOIETY

[0042] In one aspect, a novel design of amine prodrugs is provided in the current invention. In particular, the prodrugs may include a parent drug molecule having at least one amine group and at least one prodrug appendage moiety attached to an amine of the parent drug molecule.




where R is a prodrug appendage moiety where i may be 1 or 2 and j may be 0 or 1. For example, i is 1 and j is 1; or i is 2 and j is 0.




where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted.



where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and R<sup>2</sup> may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted.




where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and R<sup>3</sup> may be H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine. The metal may be Na, K, Li, Ca, Mg, Ag or Zn.



[0046] In certain exemplary embodiments, R is


where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and R<sup>3</sup> may be H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine; and R<sup>a</sup> or R<sup>b</sup> may be H, alkyl or aryl, or NR<sup>a</sup> or NR<sup>b</sup> may be an amino acid. The metal may be Na, K, Li, Ca, Mg, Ag or Zn. Aryl, or NR<sup>a</sup> or NR<sup>b</sup> may be an amino acid. The metal may be Na, K, Li, Ca, Mg, Ag or Zn.




[0047] In certain exemplary embodiments, R is

where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and X is C or O.

[0048] In certain exemplary embodiments, R is




where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> may be alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and R<sup>3</sup> may be H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine; and R<sup>a</sup> or R<sup>b</sup> may be H, alkyl or aryl, or NR<sup>a</sup> or NR<sup>b</sup> may be an amino acid. n may be 0 - 2.



[0049] In certain exemplary embodiments, R is


where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and R<sup>4</sup> may be H, metal, ammonium salt, or alkyl;

In particular, the metal may be Na, K, Li, Ca, Mg, Ag or Zn.




[0050] In certain exemplary embodiments, R is,

where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and R<sup>4</sup> may be H, metal, ammonium salt, or alkyl; k may be 1 or 2, m may be 2-22, or (CH<sub>k</sub>)<sub>m</sub> may be saturated, unsaturated or conjugated hydrocarbon. In particular, the metal may be Na, K, Li, Ca, Mg, Ag or Zn.




[0051] In certain exemplary embodiments, R is


where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl.




[0052] In certain exemplary embodiments, R is



[0053] In certain exemplary embodiments, R is




[0054] In certain exemplary embodiments, R is



[0055] In certain exemplary embodiments, R is

where R<sup>3</sup> may be H, metal, alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted, or a substituted or unsubstituted primary, secondary or tertiary amine; R<sup>a</sup> or R<sup>b</sup> may be H, alkyl or aryl, or NR<sup>a</sup> or NR<sup>b</sup> may be an amino acid.




where R<sup>1</sup> may be H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and R<sup>5</sup> may be a substituted or unsubstituted natural amino acid;

In certain embodiment, i is 1 and j is 1.


[0057] In certain embodiment, i is 2 and j is 0.

[0058] In an exemplary embodiment, the amine prodrug may be N-acyloxy carbamate prodrug formed as below,



where R<sup>1</sup> is be H or CH<sub>3</sub>; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted.

[0059] In certain exemplary embodiments, when the amine of the prodrug is a primary or secondary amine, the N-acyloxy carbamate prodrug itself may further be converted into an N-acyl compound spontaneously by intramolecular O to N acyl migration. As shown Scheme A, the N-acyl compound may be released as consequence and may substantially provide a stable carbamate compound.



Scheme A

[0060] In certain exemplary embodiments, the amine prodrugs may have improved physiochemical stability, thereby providing advantages in isolation, crystallinity, solid state stability, solubility, formulation and the like.

[0061] In certain exemplary embodiments, the amine prodrugs may have improved physiological stability when the prodrugs are taken and ingested by the subject. For example, the N-acyloxy carbamate drugs may be converted or released into the drug form more efficiently in the subject without adverse effect.


[0062] In certain exemplary embodiments, the amine prodrugs of the invention may have specificity to a certain enzymatic reaction. In yet certain embodiments, the prodrugs may be under metabolic pathway to release the active drug by enzymatic or biochemical reaction.

[0063] In certain embodiments, the amine prodrugs of the invention may provide improved cell permeability to a target cell.


[0064] In certain embodiments, the appendage moiety of the amine prodrug may provide improved physiochemical stability, improved physiological stability, or specificity to particular enzymes.

## RILUZOLE PRODRUGS

[0065] In one aspect, the current invention provides riluzole prodrugs. The riluzole prodrug may include a riluzole and at least one or more of prodrug appendage moieties attached to an amine of the riluzole at its aromatic amine.




[0066] In one embodiment, the riluzole may be coupled to one or more of prodrug appendage moieties (R) to form riluzole prodrugs. In certain embodiments, i is 1 or 2 and j is 0 or 1. For example, i is 1 and j is 1; or i is 2 and j is 0.




[0067] In certain exemplary embodiment, R is .

where  $R^1$  is H, alkyl or particularly  $C_1$ - $C_8$  alkyl;  $R^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or haloalkyl, which may be substituted or unsubstituted.




where  $R^1$  is H, alkyl or particularly  $C_1$ - $C_8$  alkyl; and  $R^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted.




[0069] In certain exemplary embodiments, R is

where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and R<sup>3</sup> is H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine.



[0070] In certain exemplary embodiments, R is


where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; R<sup>3</sup> is H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine; and R<sup>a</sup> or R<sup>b</sup> is H, alkyl or aryl or NR<sup>a</sup> or NR<sup>b</sup> is an amino acid.




[0071] In certain exemplary embodiments, R is

where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and X is C or O.


[0072] In certain exemplary embodiments, R is




where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; R<sup>3</sup> is H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine; and R<sup>a</sup> or R<sup>b</sup> is H, alkyl or aryl or NR<sup>a</sup> or NR<sup>b</sup> is an amino acid.

[0073] In certain exemplary embodiments, R is 


where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and R<sup>4</sup> is H, metal, ammonium salt, or alkyl. In particular, the metal is Na, K, Li, Ca, Mg, Ag or Zn.





where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>4</sup> is H, metal, ammonium salt, or alkyl; k is 1 or 2, m is 2-22 or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon. In particular, the metal is Na, K, Li, Ca, Mg, Ag or Zn.





where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl.




[0076] In certain exemplary embodiments, R is 



[0078] In certain exemplary embodiments, R is  

where  $R^3$  is H, metal, alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted, or a substituted or unsubstituted primary, secondary or tertiary amine;  $R^a$  or  $R^b$  is H, alkyl, aryl or  $NR^a$  or  $NR^b$  may be an amino acid.




[0079] In certain exemplary embodiments, R is  ,

where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and R<sup>5</sup> is a substituted or unsubstituted natural amino acid.

[0080] In certain embodiment, i is 1 and j is 1.

[0081] In certain embodiment, i is 2 and j is 0.

[0082] Exemplary riluzole prodrug may be, but not limited to,




where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; R<sup>3</sup> is H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine; R<sup>4</sup> is H, metal, ammonium salt, or alkyl; R<sup>6</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl; k is 1 or 2, m is 2-22, or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon; N' is a primary, secondary and tertiary amine which may be substituted or unsubstituted, or metal salts; and Y is PO<sub>3</sub>H, CH<sub>2</sub>PO<sub>3</sub>H or salt thereof. In particular, the metal is Na, K, Li, Ca, Mg, Ag or Zn.

#### SYNTHESIS OF RILUZOLE PRODRUGS


[0083] In one aspect, the riluzole prodrugs may be synthesized via intermediate form.

[0084] In one embodiment, the riluzole may be activated to produce an intermediate by reaction with methyl carboxyl group in basic condition.




[0085] The intermediate may include a good leaving group, such as halide, and may be susceptible to a nucleophilic attack from other nucleophiles. Exemplary leaving group may be, but not limited to, Cl, Br, or I.

[0086] Exemplary reaction may be described as follows:




[0087] In one exemplary embodiment, the riluzole prodrug may be formed by Scheme 1 below. In Scheme 1, Compound 1 is reacted with carboxylate metal to produce Compound 2.



Scheme 1

where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and X is Na, K, Li, Ag or Zn. Further, the metal is Na, K, Li, Ca, Mg, Ag or Zn.


[0088] In one exemplary embodiment, the riluzole prodrug may be formed by Scheme 2 below. In Scheme 2, Compound 1 is reacted with phenyl carboxylate under basic condition to produce Compound 3.



Scheme 2

where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; Y is PO<sub>3</sub>H, CH<sub>2</sub>PO<sub>3</sub>H or salts thereof; and Y' is H, PO<sub>3</sub>Bc<sub>2</sub>, CH<sub>2</sub>PO<sub>2</sub>Bc, MPO<sub>3</sub>Bc or salt thereof, or N(R<sub>a</sub>)<sub>4</sub><sup>+</sup>, where Ra is H or alkyl.


[0089] In one exemplary embodiment, the riluzole prodrug may be formed by Scheme 3 below. In Scheme 3, Compound 1 is reacted with protected phosphate and the resulting compound is deprotected to produce Compound 3.



Scheme 3


where  $R^1$  is H, alkyl or particularly  $C_1$ - $C_8$  alkyl;  $R^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted;  $R^3$  is H, metal,  $R^2$  or a substituted or unsubstituted primary, secondary or tertiary amine; and  $Bc$  is a protecting group.  $M$  is a metal including Na, K, Li, Ca, Mg, Ag or Zn.

[0090] In one exemplary embodiment, the riluzole prodrug may be formed by Scheme 4 and Scheme 4' below. In Scheme 4, Compound 1 is reacted with fumarate to produce Compound 5



Scheme 4


[0091] In Scheme 4', Compound 1 is reacted with a saturate, unsaturated, or conjugated dicarboxylic acid to produce Compound 5'.



Scheme 4'

[0092] In Schemes 4 and 4', R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>4</sup> is H, metal, ammonium salt, or alkyl; k is 1 or 2, m is 2-22, or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon; and M is a metal including Na, K, Li, Mg, Ca, Ag or Zn.


[0093] In one exemplary embodiment, the riluzole prodrug may be formed by Scheme 5 below. In Scheme 5, Compound 1 is reacted with protected aminoacetate and the resulting compound is deprotected to produce Compound 6.



Scheme 5

where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted; and R<sup>5</sup> is a substituted or unsubstituted natural amino acid; and M is a metal including Na, K, Li, Mg, Ca, Ag or Zn. Bc is a protecting group.

[0094] In one exemplary embodiment, the riluzole prodrug may be formed by Scheme 6 below. In Scheme 6, Compound 1 is reacted with aminoacetate to produce Compound 7.




Scheme 6

where  $R^1$  is H, alkyl or particularly  $C_1$ - $C_8$  alkyl; and  $R^5$  is a substituted or unsubstituted natural amino acid; and X is Na, K, Li, Ag or Zn.

[0095] In another embodiment, the riluzole prodrug may be formed using cesium carbonate for carbamination of amine efficiently.


[0096] In one exemplary embodiment, the riluzole prodrug may be formed in N-acyloxy carbamate form. In Scheme 7, activated carboxylic acid and carbon dioxide are condensed with riluzole to form the prodrug (compound 8).



Scheme 7

where  $\text{R}^1$  is H, alkyl or particularly  $\text{C}_1\text{-C}_8$  alkyl;  $\text{Lg}$  is a leaving group;  $\text{R}^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which may be substituted or unsubstituted. In particular,  $\text{Lg}$  may be a halide, such as F, Cl, Br and I.

[0097] In Scheme 8, riluzole is reacted with 4-methyl 1,3-dioxol-2-one to produce Compound 9. In an exemplary embodiment, the prodrug may be synthesized as follows.




Scheme 8

where  $\text{R}^1$  is H, alkyl or particularly  $\text{C}_1\text{-C}_8$  alkyl;  $\text{Lg}$  is a leaving group  $\text{Lg}$  is a leaving group. Particularly,  $\text{Lg}$  may be a halide, such as F, Cl, Br and I.

[0098] In Scheme 9, riluzole is reacted with isobenzofuran-1-one to produce Compound 10.

[0099] In an exemplary embodiment, the prodrug may be synthesized as follows.




Scheme 9

[0100] In particular, Lg is a leaving group. Lg may be a halide, such as F, Cl, Br and I.


[0101] In Scheme 10, riluzole is reacted with  $((\text{PhCH}_2\text{O})_2\text{PO})_2\text{O}$  and sodium bis(trimethylsilyl)amide (NaHMDS) and the resulting compound is reacted with hydrogen gas to produce compound 11.

[0102] In an exemplary embodiment, the prodrug may be synthesized as follows:




where  $\text{R}^6$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl; and  $\text{N}'$  is a primary, secondary and tertiary amine which is substituted or unsubstituted, or metal salts.

[0103] In one exemplary embodiment, N-acyloxy carbamate prodrug may also be synthesized



where  $\text{R}^1$  is H, alkyl or particularly  $\text{C}_1\text{-C}_8$  alkyl; and  $\text{R}^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which is substituted or unsubstituted. Exemplary reaction scheme is shown as follows. In Scheme 11, riluzole is reacted with ((4-nitrophenoxy)carbonyloxy)methyl formate to produce Compound 12.



Scheme 11


[0104] The entire contents of all patents, published patent applications and other references cited herein are hereby expressly incorporated herein in their entireties by reference.

[0105] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein.

Such equivalents are considered to be within the scope of this invention and are covered by the following claims.


## WE CLAIM:


1. A prodrug comprising a drug molecule and at least one or more prodrug appendage moieties, the prodrug is formed as:



wherein the prodrug appendage moiety is coupled to amine of the drug molecule, and i is 1 or 2 and j is 0 or 1.

2. The prodrug of claim 1, wherein the prodrug appendage moiety is independently selected from the group of consisting of:





where  $R^1$  is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl;

$R^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which is substituted or unsubstituted,

$R^3$  is H, metal,  $R^2$  or a substituted or unsubstituted primary, secondary or tertiary amine;

$R^4$  is H, metal, ammonium salt or alkyl;

$R^5$  is a substituted or unsubstituted natural amino acid;

$R^a$  or  $R^b$  is H, alkyl or aryl; or  $NR^a$  or  $NR^b$  is an amino acid;

X is C or O;

k is 1 or 2, m is 2-22, or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon;

n is 0 – 2;


the metal is Na, K, Li, Ca, Mg, Ag or Zn.

3. The prodrug of claim 1, wherein i is 1 and j is 1.

4. The prodrug of claim 1, wherein i is 2 and j is 0.


5. The prodrug of claim 1, wherein the drug molecule is riluzole.

6. A method of preparing a riluzole prodrug, comprising a step of coupling one or more prodrug appendage moieties to a riluzole molecule



wherein the prodrug appendage moiety is coupled to amine of the riluzole molecule, and i is 1 or 2 and j is 0 or 1.

7. The method of claim 6, wherein each prodrug appendage moiety is independently selected from the group of consisting of:



where  $R^1$  is H, alkyl or particularly  $C_1$ - $C_8$  alkyl;

$R^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which is substituted or unsubstituted,

$R^3$  is H, metal,  $R^2$  or a substituted or unsubstituted primary, secondary or tertiary amine;

$R^4$  is H, metal, ammonium salt or alkyl;

$R^5$  is a substituted or unsubstituted natural amino acid;

R<sup>a</sup> or R<sup>b</sup> is H, alkyl or aryl; or NR<sup>a</sup> or NR<sup>b</sup> is an amino acid;

X is C or O;

k is 1 or 2, m is 2-22, or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon;

n is 0 – 2;


m is 2-12; and


the metal is Na, K, Li, Mg, Ca, Ag or Zn.

8. The method of claim 6, wherein i is 1 and j is 1.

9. The method of claim 6, wherein i is 2 and j is 0.

10. The method of claim 6, wherein the riluzole prodrug is selected from the group consisting of:





where R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which is substituted or unsubstituted;

R<sup>3</sup> is H, metal, R<sup>2</sup> or a substituted or unsubstituted primary, secondary or tertiary amine;

R<sup>4</sup> is H, metal, ammonium salt or alkyl;

R<sup>5</sup> is a substituted or unsubstituted natural amino acid;

R<sup>6</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl;



k is 1 or 2, m is 2-22, or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon;

N' is a primary, secondary and tertiary amine which is substituted or unsubstituted, or metal salts;


Y is PO<sub>3</sub>H, CH<sub>2</sub>PO<sub>3</sub>H or salt thereof; and

the metal is Na, K, Li, Ca, Mg, Ag or Zn.


11. A method of synthesizing a riluzole prodrug, comprising a step of reacting riluzole with





to produce



12. The method of claim 11, further comprising a step of reacting



with a compound selected from the group consisting of:



wherein R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl;

R<sup>2</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which is substituted or unsubstituted;

R<sup>4</sup> is H, metal, ammonium salt, or alkyl,

k is 1 or 2, m is 2-22, or (CH<sub>k</sub>)<sub>m</sub> is saturated, unsaturated or conjugated hydrocarbon;

Bc is a protecting group;

Y' is H, PO<sub>3</sub>Bc<sub>2</sub>, CH<sub>2</sub>PO<sub>2</sub>Bc, MPO<sub>3</sub>Bc or salt thereof, or N(R<sub>a</sub>)<sub>4</sub><sup>+</sup>, where Ra is H or alkyl;

M is Na, K, Li, Mg, Ca, Ag or Zn; and

R' or R'' are cyclic or acyclic alkyl.


13. A method of synthesizing a riluzole prodrug, comprising a step of reacting a riluzole,

with CO<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub> and reacting the resulting compound with R<sup>3</sup>O-C(=O)-O-Lg, wherein Lg is a leaving group.


14. A method of synthesizing a riluzole prodrug, comprising a step of reacting a riluzole

with , wherein Lg is a leaving group and where R<sup>1</sup> is H, or C<sub>1</sub>-C<sub>8</sub> alkyl.

15. A method of synthesizing a riluzole prodrug, comprising a step of reacting a




16. A method of synthesizing a riluzole prodrug, comprising a step of reacting riluzole



wherein R<sup>1</sup> is H, alkyl or particularly C<sub>1</sub>-C<sub>8</sub> alkyl; and

$R^2$  is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl, which is substituted or unsubstituted.

17. A method of synthesizing a riluzole prodrug, comprising a step of reacting riluzole with  $((\text{PhCH}_2\text{O})_2\text{PO})_2\text{O}$  and sodium bis(trimethylsilyl)amide (NaHMDS) and subsequently reacting the resulting compound with hydrogen:



wherein R<sup>6</sup> is alkyl, cycloalkyl, aryl, or heteroaryl, or halo alkyl; N' is a primary, secondary and tertiary amine which is substituted or unsubstituted, or metal salts.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/62400

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 47/48, A61K 9/14, A61P 25/16 (2016.01)

CPC - A61K 47/4823, A61K 47/48315, A61K 47/48338

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 47/48, A61K 9/14, A61P 25/16 (2016.01)

CPC - A61K 47/4823, A61K 47/48315, A61K 47/48338

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Patbase, Google Scholar, PubChem; Riluzole, prodrugs, dioxol-2-one, amine, pharmaceutical, phthalide, isobenzofuranone, tetrabenzylyl pyrophosphate, bis(trimethylsilyl)amine, NaHMDS, hydrogenation

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2015/0111932 A1 (Kandula et al.) 23 April 2015 (23.04.2015); para[0032], para[0038], para[0141], para[0142], para[0143], page7, page21	1-3, 5-8, 10-12
---		-----
Y		13-17
X	US 2004/0176430 A1 (Sterling et al.) 09 September 2004 (09.09.2004); para[0077], para[0168]	1, 4, 6, 9
Y	Salvatore et al., 'Efficient Carbamate Synthesis via a Three-Component Coupling of an Amine, CO <sub>2</sub> , and Alkyl Halides in the Presence of Cs <sub>2</sub> CO <sub>3</sub> and Tetrabutylammonium Iodide', The Journal of Organic Chemistry, 6 January 2001 (06.01.2001), Vol. 66, page 1035-1037; page1035	13
Y	WO 2014/011695 A2 (Onyx Therapeutics, Inc.) 16 January 2014 (16.01.2014); page168, Fig.38	14
Y	Stark et al., 'Enzyme-Catalyzed Prodrug Approaches for the Histamine H3-Receptor Agonist (R)-Methylhistamine', Bioorganic & Medicinal Chemistry, 15 December 2000 (15.12.2000), Vol. 9, pages 191-198; page193, page197	15
Y	US 2003/0216469 A1 (Bryans et al.) 20 November 2003 (20.11.2003); para[0074]	16
Y	Hale et al. 'Phosphorylated Morpholine Acetal Human Neurokinin-1 Receptor Antagonists as Water-Soluble Prodrugs', Journal of Medicinal Chemistry, 25 February 2000 (25.02.2000), Vol.43, page1234-1241; page1234, page1235, page1237, Schome3	17
A	US 2013/0030359 A1 (Vetter et al.) 31 January 2013 (31.01.2013); entire document	1-17

Further documents are listed in the continuation of Box C.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search  
27 December 2016

Date of mailing of the international search report  
02 FEB 2017

Name and mailing address of the ISA/US  
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-8300

Authorized officer:  
Lee W. Young  
PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774